A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006209
Recruitment Status : Unknown
Verified June 2001 by NIH AIDS Clinical Trials Information Service.
Recruitment status was:  Active, not recruiting
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service

September 11, 2000
August 31, 2001
June 24, 2005
June 2000
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
A Phase I Open-Label Dose Escalation Trial of Tucaresol in HIV-1 Infected Subjects Taking Potent Antiretroviral Therapy
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART). This study also examines the effect tucaresol has on viral load (level of HIV in the body) when tucaresol is used with HAART.
Patients are enrolled sequentially into the next available dosage cohort. Each cohort receives a single dose of tucaresol, is observed for 2 weeks, and then receives 3 alternate-day doses of drug and careful safety monitoring, including 4 weeks follow-up after the final dose. Dose cohorts receive drug sequentially, the lowest-dose cohort receiving the drug first. Dose escalation may not proceed to the next higher-dose cohort until all patients from the prior lower-dose cohort have completed the 4-week follow-up after the multiple dosing, adverse events are within the described bounds, and the FDA has reviewed the safety information from the treated cohort and approved the dose escalation. The drug is administered 4 times within the 8 weeks of the study period. Weekly visits are required. Patients receive financial compensation.
Phase 1
Primary Purpose: Treatment
HIV Infections
Drug: Tucaresol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
Not Provided
Not Provided

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are at least 18 years old.
  • Are HIV-positive.
  • Have more than 300 CD4 T cells/microL at screening.
  • Are taking certain anti-HIV drugs.
  • Have been taking these anti-HIV drugs successfully for at least 6 months.
  • Do not expect to change their anti-HIV therapy while they are in the study.
  • Have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy.
  • Have viral load that cannot be detected at screening and baseline tests.
  • Are able to complete weekly visits.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Cannot give informed consent.
  • Have abnormal laboratory test results at baseline.
  • Are pregnant or breast-feeding.
  • Have had certain short-term or long-term illnesses (such as heart disease, sickle cell disease, anemia, or lung problems).
  • Have received a vaccination within the 30 days prior to enrollment.
  • Have received any other experimental drug within 60 days of enrollment.
  • Are taking abacavir (Ziagen, GW1592) or drugs that affect the immune system, such as IL-2, GM-CSF, corticosteroids, or cyclosporine.
  • Have a history of tumors.
  • Are actively using illegal drugs (methadone is allowed).
  • Have hepatitis B or hepatitis C.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Aaron Diamond AIDS Research Center
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
June 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP